tradingkey.logo

Vanda Pharmaceuticals Inc <VNDA.OQ> expected to post a loss of 11 cents a share - Earnings Preview

ReutersFeb 3, 2025 12:17 PM
  • Vanda Pharmaceuticals Inc VNDA.OQ VNDA.O is expected to show a rise in quarterly revenue when it reports results on February 5 (estimated) for the period ending December 31 2024

  • The Washington Washington Dc-based company is expected to report a 15.4% increase in revenue to $52.248 million from $45.27 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Vanda Pharmaceuticals Inc is for a loss of 11 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Vanda Pharmaceuticals Inc is $9.25​, above​ its last closing price of $4.41. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.16

-0.16

-0.09

Beat

44.9

Jun. 30 2024

-0.21

-0.21

-0.08

Beat

61.9

-0.07

Dec. 31 2023

-0.09

-0.09

-0.04

Beat

55.6

​​Sep. 30 2023

-0.04

-0.04

0.00

Beat

100

Jun. 30 2023

-0.13

-0.13

0.03

Beat

123.1​

Dec. 31 2022

0.08

0.08

0.12

Beat

50

This summary was machine generated February 3 at 12:17 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: For information purposes only. Past performance is not indicative of future results.

Related Articles